CAPE was shown to provide neuroprotection by inhibiting NF-kB function and reducing the release of proinflammatory miRNAs (miRNA-125b, miRNA-146a and miRNA-155) from primary human neuronal glial cells stressed with Alzheimer’s disease (AD) derived extracellular fluid [102]. The gene discussed is NFKB1; the disease is Alzheimer disease.